Literature DB >> 25197969

CD4+CD25highFOXP3+ T regulatory cells as a biomarker of disease activity in systemic lupus erythematosus: a prospective study.

Konstantinos Tselios1, Alexandros Sarantopoulos, Ioannis Gkougkourelas, Panagiota Boura.   

Abstract

OBJECTIVES: Several studies have reported low numbers of T regulatory cells (Tregs) in active systemic lupus erythematosus (SLE). However, it is not evident if these cells may be utilised as a biomarker in assessing disease activity.
METHODS: Tregs (CD4+CD25highFOXP3+) were prospectively assessed by flow cytometry in 285 separate blood samples from 100 white Caucasian SLE patients and 20 healthy controls. Patients were divided, according to disease activity (as measured by SLEDAI) into groups A (n=39, samples=94, SLEDAI=0), B (n=33, samples=92, SLEDAI=1-5), C (n=10, samples=53, SLEDAI=6-10) and D (n=18, samples=46, SLEDAI>10). Longitudinal measurements were performed in 131 cases (37 relapses, 44 remissions and 50 cases with stable disease activity) during three years. Statistics were performed by Student's t-test or one-way ANOVA; correlations with Pearson co-efficient, while p<0.05 was considered significant.
RESULTS: Tregs were found significantly lower in severely active disease (group D), compared to healthy controls, inactive disease, mild and moderate disease activity (0.57±0.16% vs. 1.49±0.19%, 1.19±0.34% and 1.05±0.36%, 0.72±0.21%, p<0.05, respectively). There was a strongly inverse correlation between Tregs and SLEDAI (r=-0.644, p<0.001). Alterations in disease activity were characterised by inverse alterations in Tregs: relapse (from 1.23±0.44% to 0.64±0.19%, p<0.001, mean change 0.59±0.41%), remission (from 0.65±0.27% to 1.17±0.30%, p<0.001, mean change 0.52±0.35%). In cases with unaltered disease activity, Treg numbers remained stable (from 0.98±0.35% to 1.03±0.34%, p=0.245). Tregs were practically halved during relapse (mean reduction 42.6±22.2%), and doubled during remission (mean increment 113±120.9%). Mean change of Tregs in stable disease was significantly lower (7.3±20.6%, p<0.001). A clinically significant change in SLEDAI (sum of cases with relapse and remission, n=81) was followed by a significant (>20%) inverse change in Tregs in 71/81 cases (sensitivity 87.7%). In 50 cases of stable disease activity, Tregs were significantly changed (>20%) in 13 cases (specificity 74%). Positive predictive value (PPV) was 84.5% and negative predictive value (NPV) was 78.7%.
CONCLUSIONS: CD4+CD25highFOXP3+ T regulatory cells displayed a strongly inverse correlation to disease activity in the long term. Treg alterations reflected changes in SLEDAI with high sensitivity. These cells may be a reliable biomarker for the assessment of disease activity in SLE by longitudinal measurements.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25197969

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  14 in total

Review 1.  Treg cells in autoimmunity: from identification to Treg-based therapies.

Authors:  Lisa Göschl; Clemens Scheinecker; Michael Bonelli
Journal:  Semin Immunopathol       Date:  2019-04-05       Impact factor: 9.623

2.  The regulation of the Treg/Th17 balance by mesenchymal stem cells in human systemic lupus erythematosus.

Authors:  Dandan Wang; Saisai Huang; Xinran Yuan; Jun Liang; Renju Xu; Genhong Yao; Xuebing Feng; Lingyun Sun
Journal:  Cell Mol Immunol       Date:  2015-10-05       Impact factor: 11.530

3.  Analysis of FOXP3+ regulatory T cell subpopulations in peripheral blood and tissue of patients with systemic lupus erythematosus.

Authors:  Angelika Schmidt; Cosima C Rieger; Ram Kumar Venigalla; Szabolcs Éliás; Regina Max; Hanns-Martin Lorenz; Hermann-Josef Gröne; Peter H Krammer; Annegret Kuhn
Journal:  Immunol Res       Date:  2017-04       Impact factor: 2.829

Review 4.  Modulation of Mesenchymal Stem Cells-Mediated Adaptive Immune Effectors' Repertoire in the Recovery of Systemic Lupus Erythematosus.

Authors:  Akram Hoseinzadeh; Zahra Rezaieyazdi; Jalil Tavakol Afshari; Ali Mahmoudi; Sahar Heydari; Reza Moradi; Seyed-Alireza Esmaeili; Mahmoud Mahmoudi
Journal:  Stem Cell Rev Rep       Date:  2022-10-22       Impact factor: 6.692

5.  High interleukin-18 and low FOXP3 mRNAs in peripheral blood of women with severe systemic lupus erythematosus: a cross-sectional study.

Authors:  Lyuba D Miteva; Irena M Manolova; Mariana G Ivanova; Rumen M Stoilov; Spaska A Stanilova
Journal:  Rheumatol Int       Date:  2020-03-09       Impact factor: 2.631

Review 6.  Epigenetic Variability of CD4+CD25+ Tregs Contributes to the Pathogenesis of Autoimmune Diseases.

Authors:  Ye Shu; Qinghua Hu; Hai Long; Christopher Chang; Qianjin Lu; Rong Xiao
Journal:  Clin Rev Allergy Immunol       Date:  2017-04       Impact factor: 8.667

7.  The Regulatory T Cell in Active Systemic Lupus Erythematosus Patients: A Systemic Review and Meta-Analysis.

Authors:  Wenli Li; Chuiwen Deng; Hanbo Yang; Guochun Wang
Journal:  Front Immunol       Date:  2019-02-18       Impact factor: 7.561

8.  Regulatory T Cells Compensation Failure Cause the Dysregulation of Immune Response in Pristane Induced Lupus Mice Model.

Authors:  Handono Kalim; Mirza Zaka Pratama; Aditya Satriya Nugraha; Multi Prihartini; Afriska Chandra; Al Imroatus Sholihah; Fatina Qonita; Kusworini Handono
Journal:  Malays J Med Sci       Date:  2018-06-28

Review 9.  The Proportion of Regulatory T Cells in Patients with Systemic Lupus Erythematosus: A Meta-Analysis.

Authors:  Sheng-Xiao Zhang; Xiao-Wen Ma; Yu-Feng Li; Na-Ling Lai; Ze-Hao Huang; Kai Fan; Cai-Hong Wang; Xiao-Feng Li
Journal:  J Immunol Res       Date:  2018-09-03       Impact factor: 4.818

Review 10.  Mesenchymal Stem Cells: Allogeneic MSC May Be Immunosuppressive but Autologous MSC Are Dysfunctional in Lupus Patients.

Authors:  Rui-Juan Cheng; An-Ji Xiong; Yan-Hong Li; Shu-Yue Pan; Qiu-Ping Zhang; Yi Zhao; Yi Liu; Tony N Marion
Journal:  Front Cell Dev Biol       Date:  2019-11-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.